Navigation Links
New hope for setback-dogged cancer treatment
Date:11/26/2012

Several drugs companies have ineffectively tried to produce antibodies that bind to the IGF-1 receptor on the cell surface, which has a critical part to play in the development of cancer. Scientists at Karolinska Institutet in Sweden have now ascertained how these antibodies work, and can explain why only some cancer patients are helped by IGF-1 blockers during clinical tests. The researchers also present a means by which drugs of this kind could help more cancer patients.

Every cell contains thousands of tiny receptors that help it communicate with other cells. These receptors are involved in countless physiological processes, such as taste and smell perception and heart rate. A couple of dozen of these receptors form their own family the kinase receptors (RTKs), which are implicated in cancer. The so-called IGF-1 receptor is particularly important for cancer cell survival, and as soon as this receptor encounters the right hormone (type 1 insulin-like growth factor, or IGF-1) into the cancer cell open a number of communication channels, helping it to grow, rapidly divide and protect itself against treatment.

Blocking this receptor with an antibody that binds to it and makes it inaccessible to IGF-1 has long been regarded as the key to a potential cancer therapy, the idea being that it will eventually lead to the death of the tumour cell. Several drugs companies have therefore been developing such antibodies in order to treat the most aggressive forms of cancer, and after some promising laboratory tests, have tested a number of these preparations on patients. However, the drugs have generally given disappointing results and helped only a small minority of patients (including children with Ewing's sarcoma), leading some companies to discontinue clinical trials focusing on the IGF-1 receptor.

The Karolinska Institutet team has now systematically analysed the different IGF-1-related triggered communication channels within a cancer cell. Their results show that the original idea is correct and that such antibody treatment does actually stop the channels from opening, with one very important exception: the MEK channel was actually powerfully stimulated by the treatment the antibodies being as effective in this as the hormone itself and actively helped the cancer cells to survive.

"This gives us a credible explanation why the antibody trials for the IGF-1 receptor weren't as effective as had been hoped," says principal investigator Dr Leonard Girnita, docent of pathology at Karolinska Institutet's Department of Oncology-Pathology. "So it's too early to give up on the idea of treating cancer like this it's still a very good way of attacking the cancer, provided we can close this final communication channel. If we can do this, antibodies for the IGF-1 receptor are likely to form an effective treatment not only for Ewing's sarcoma in children but many other cancers as well."

Drugs that are used to close this channel in other forms of treatments are already available. The researchers believe that a combination therapy using such MEK inhibitors with IGF-1 blockers can be the key to releasing the potential of this therapy model.

"We've seen in the laboratory that cell lines treated in this way no longer manage to divide," says Dr Girnita. "When they die of old age there is no regrowth, so we've seen in the laboratory environment how cancer cells die out of their own accord."


'/>"/>

Contact: Press Office
pressinfo@ki.se
46-852-486-077
Karolinska Institutet
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. New Stool Test Might Aid in Early Detection of Colon Cancer
3. Study reveals how cancer drug causes diabetic-like state
4. How a cancer drug leads to diabetes
5. You Survived Cancer: Now Pay Attention to Your Overall Health
6. New drug prevents spread of human prostate cancer cells
7. Eliminating the good cholesterol receptor may fight breast cancer
8. Taller, Heavier Women May Face Higher Ovarian Cancer Risk
9. Experimental Chemo Combo for Colon Cancer Disappoints
10. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
11. Targeted therapeutics for colon cancer to be presented at AACR meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2017)... ... ... Getting earned media coverage meaningful for Garden Media Group's clients is the ... Garden Media aims to provide material helpful to clients’ goals and bottom lines. By ... messages to gain coveted media placements, Garden Media wows clients year-round. , Here ...
(Date:3/24/2017)... ... 24, 2017 , ... Clean Earth, Inc., a leader in ... non-hazardous materials announced today the acquisition of privately owned AERC Recycling Solutions ... processing facilities and a vast array of additional technologies, services, and new markets ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... which will spark a conversation on the current obstacles facing infection prevention and ... completely preventable deaths caused by these infections. , The print component of ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... Digital Scientists, ... excited to announce the opening of a Greenville, South Carolina location. The ... digital progress in Greenville. , “We’ve been working with South Carolina clients for years ...
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new study by NCPA Senior ... not obey the rules Congress has directed the CBO to follow. The CBO itself ... would restore. Yet, it estimates a reduction in employer-based coverage due to the GOP ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Texas , March 27, 2017   Genprex, Inc. , ... that Julien Pham , MD, the Company,s Chief Operating Officer, ... investor conferences. Sachs 5th Annual Cancer BioPartnering & ... New York, NY ... BioCentury 24th Annual Future Leaders in ...
(Date:3/24/2017)... , March 24, 2017 According to a new report ... and Industry Forecast, 2014-2022," the spine bone stimulators market was valued at $562 ... at a CAGR of 3.6% during the forecast period. ... ... Research Logo ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of the ... offering. ... the worldwide markets for Dental Implants in US$ Million. The report provides ... Japan , Europe , Asia-Pacific ... Annual estimates and forecasts are provided for the period ...
Breaking Medicine Technology: